Cargando…
Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
Pancreatic ductal adenocarcinoma (PDAC) is one of the most overlooked cancers despite its dismal median survival time of 6 months. The biggest challenges in improving patient survival are late diagnosis due to lack of diagnostic markers, and limited treatment options due to almost complete therapy r...
Autores principales: | Gündel, Beate, Liu, Xinyuan, Löhr, Matthias, Heuchel, Rainer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569794/ https://www.ncbi.nlm.nih.gov/pubmed/34746135 http://dx.doi.org/10.3389/fcell.2021.741162 |
Ejemplares similares
-
3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma
por: Liu, Xinyuan, et al.
Publicado: (2021) -
DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021) -
Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022) -
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023) -
GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021)